Como avaliar a operabilidade de um doente

Hoy H, Beck M. Surgical Treatment of Lung Cancer. Crit Care Nurs Clin N Am. 2019; 31(3):303-313. Doi: 10.1016/j.cnc.2019.05.002.

Ganti A ey al. Small Cell Lung Cancer - NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 12: 1441-1464. Doi: 10.6004/jnccn.2021.0058.

Shamji FM, Beauchamp Gilles. Assessment of Operability in Lung Cancer. Thorac Surg Clin. 2021; 31: 379-391. Doi: 10.1016/j.thorsurg.2021.07.008.

Ichinokawa H, Takamochi K, Fukui M, Hattori A, Matsunaga T, Suzuki K. Surgical results and prognosis of lung cancer in elderly Japanese patients aged over 85 years: comparison with patients aged 80 – 84 years. Gen Thorac and Cardiocardiovasc Surg. 2021; 69: 67-75. Doi: 10.1007/s11748-020-01426-y.

Brunelli A, Gooseman M, Pompili C. Evaluation of risk for thoracic surgery. Surg Oncol Clin N Am 29 (2020) 497-508. Doi:10.1016/j.soc.2020.06.001.

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO – Clinical Practice Guidelines. 2017; 28, suppl 4: iv1-iv21. Doi: 10.1093/annonc/mdx222.

Batchelor T, Rasburn NJ, Adelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, Ljungqvist O, Peterson RH, Popescu WM, Slinger PD, Naidu B. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS) Society and the European Society of Thoracic Surgery (ESTS); Eur J Cardiothoracic Surg. 2019; 55: 91-115. Doi: 10.1093/ejcts/ezy301.

Lim E, Batchelor T, Dunning J. Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: 1-year results from a randomised controlled trial (VIOLET). J Clin Oncol. 2021; 39, suppl.8504. Doi: 10.1200/JCO.2021.39.15.

Saji H, Okada M, Asamura H. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022; 399(10335):1607-1617. Doi: 10.1016/S0140-6736(21)02333-3.